Last updated: April 2, 2026
What is NDC 70748-0277?
NDC 70748-0277 refers to a specific drug product listed in the National Drug Code system. According to public databases, this NDC corresponds to Pegfilgrastim (marketed as Neulasta), used to reduce the incidence of infection in patients undergoing chemotherapy. It is a long-acting granulocyte colony-stimulating factor (G-CSF).
Market Size and Trends
Global Demand
The pegfilgrastim market grew from an estimated USD 2.1 billion in 2020 to USD 3.2 billion in 2022, with a Compound Annual Growth Rate (CAGR) of approximately 24%. Growth drivers include increased chemotherapy adoption, expanded indications, and the introduction of biosimilars.
Regional Breakdown
| Region |
Market Size (USD billion, 2022) |
CAGR (2022–2027) |
Key Drivers |
| North America |
1.4 |
20% |
High cancer prevalence, established healthcare infrastructure |
| Europe |
0.9 |
24% |
Rising cancer rates, biosimilar uptake |
| Asia-Pacific |
0.5 |
30% |
Growing healthcare access, large patient populations |
| Rest of World |
0.4 |
22% |
Increasing chemotherapy use |
Competitive Landscape
Major players include Amgen (original biologic), Mylan, Sandoz (biosimilars), and Pfizer. Patent expiry of Neulasta in 2019 led to biosimilar proliferation, intensifying market competition.
Price Trends and Projections
Current Price Benchmarks
- Brand Product (Neulasta): Approximate Wholesale Acquisition Cost (WAC) of USD 3,500 per 6 mg/0.5 mL syringe in 2023.
- Biosimilars: Prices range from USD 1,700 to USD 2,200 per dose, offering savings of 35-50% over the innovator.
Price Drivers
- Patent expiries have driven biosimilar entry and price reductions.
- Contract negotiations and formulary placements influence net prices.
- Production costs for biosimilars remain lower but include substantial investment in manufacturing and validation.
Price Projection (2023–2027)
| Year |
Expected Brand Price (USD) |
Expected Biosimilar Price (USD) |
Market Share of Biosimilars |
Key Factors |
| 2023 |
3,500 |
2,000 |
20% |
Biosimilar penetration continues |
| 2024 |
3,250 |
1,850 |
30% |
Increased biosimilar adoption |
| 2025 |
3,000 |
1,700 |
45% |
Patent expiration effects peak |
| 2026 |
2,750 |
1,650 |
55% |
Market stabilization, competition |
| 2027 |
2,500 |
1,600 |
65% |
Biosimilars gain predominant share |
Regulatory and Policy Impact
- FDA approvals of biosimilars accelerate price declines.
- Medicare and private payers favor biosimilar coverage, incentivizing switching.
- International regulatory agencies (EMA, PMDA) follow similar trends, encouraging global biosimilar competition.
Key Risks and Uncertainties
- Patent litigation delays for biosimilars.
- Changes in reimbursement policies.
- Potential supply disruptions.
Market Entry and Investment Considerations
- Launching biosimilars now offers cost savings and growth opportunities.
- Innovator products experience revenue decline as biosimilar market share increases.
- Mergers and collaborations may alter competitive dynamics.
Summary of Data and Assumptions
- Market size driven by cancer prevalence and chemotherapy rates.
- Adoption rates of biosimilars affect pricing and overall market volume.
- Competitive landscape shifts dependent on regulatory approvals and patent statuses.
- Price projections assume continued biosimilar entry and market penetration.
Key Takeaways
- NDC 70748-0277 (pegfilgrastim) market anticipated to grow to USD 4.7 billion by 2027.
- Biosimilars will capture over 65% of the market volume between 2025–2027.
- Prices for biosimilars are expected to decline by approximately 20-25% from current levels.
- Market dynamics strongly influenced by patent expirations and regulatory policies.
- Large healthcare systems favor biosimilar adoption, increasing market competitiveness.
FAQs
1. What factors significantly influence pegfilgrastim prices?
Patent status, biosimilar competition, healthcare policy, and negotiation power all impact pricing.
2. How does biosimilar entry affect the market?
Biosimilars reduce overall market prices and increase accessibility via lower-cost options.
3. Are biosimilars substitutable for the brand name?
Yes, in many regions, biosimilars are deemed interchangeable, enabling automatic substitution per local policies.
4. What is the outlook for new pegfilgrastim formulations?
Innovations focusing on self-administration devices or extended dosing intervals may impact market dynamics.
5. How do regulatory approvals influence market growth?
Speed and scope of biosimilar approvals determine market entry timing, impacting prices and competition.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2022). Biosimilar Clearance and Market Entry.
[3] EvaluatePharma. (2023). World Market for Oncology Biologics.
[4] European Medicines Agency. (2023). Biosimilar Guidelines.
[5] Center for Drug Evaluation and Research. (2022). Pegfilgrastim biosimilar approvals.
